A

Agios Pharmaceuticals
D

AGIO

38.185
USD
-1.12
(-2.84%)
مغلق
حجم التداول
25,091
الربح لكل سهم
-7
العائد الربحي
-
P/E
3
حجم السوق
2,218,606,465
أصول ذات صلة
C
CRSP
-0.440
(-0.82%)
53.060 USD
E
EDIT
-0.02500
(-0.93%)
2.65000 USD
N
NTLA
0.190
(1.67%)
11.600 USD
Q
QURE
0.480
(3.04%)
16.260 USD
R
RARE
0.240
(0.80%)
30.290 USD
S
SGMO
0.00200
(0.37%)
0.54190 USD
S
SRPT
0.250
(1.38%)
18.335 USD
المزيد
الأخبار المقالات

العنوان: Agios Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.